| Drug ID: | Drug86 |
|---|---|
| Drug Name: | Vitamin K |
| CID: | 5280483 |
| DrugBank ID: | NULL |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT01839214 |
| Molecular Formula: | C31H46O2 |
| Molecular Weight: | 450.7 g/mol |
| Isomeric SMILES: | CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\\C)/CCCC(C)CCCC(C)CCCC(C)C |
| Synonyms: | VITAMIN K; 12001-79-5; 81818-54-4; Kephton; 2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; Vitamin K1(20); .alpha.-Phylloquinone; 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; 3-methyl-2-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)naphthalene-1,4-dione |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt716 | 5280483 | Vitamin K | 2147 | F2 | Homo sapiens (human) | Cofactor | |
| dt717 | 5280483 | Vitamin K | 59 | ACTA2 | Rattus norvegicus (Norway rat) | 23117658 | [warfarin co-treated with vitamin K co-treated with quercetin] results in increased expression of ACTA2 mRNA |
| dt718 | 5280483 | Vitamin K | 105387 | Akr1c14 | Rattus norvegicus (Norway rat) | 16844298 | Vitamin K affects the expression of AKR1C14 mRNA |
| dt719 | 5280483 | Vitamin K | 348 | APOE | Homo sapiens (human) | 15952022 | APOE protein affects the abundance of vitamin K |
| dt720 | 5280483 | Vitamin K | 348 | APOE | Homo sapiens (human) | 16847429 | APOE protein affects the uptake of vitamin K |
| dt721 | 5280483 | Vitamin K | 8313 | AXIN2 | Rattus norvegicus (Norway rat) | 23117658 | Quercetin inhibits the reaction [[warfarin co-treated with vitamin K] results in increased expression of AXIN2 mrna]|[warfarin co-treated with vitamin K] results in increased expression of AXIN2 mRNA |
| dt722 | 5280483 | Vitamin K | 558 | AXL | Homo sapiens (human) | 26206560 | Vitamin K results in increased expression of AXL protein modified form|vitamin K inhibits the reaction [warfarin results in decreased expression of AXL protein modified form] |
| dt723 | 5280483 | Vitamin K | 632 | BGLAP | Rattus norvegicus (Norway rat) | 23117658 | [warfarin co-treated with vitamin K] results in increased expression of BGLAP mrna|quercetin inhibits the reaction [[warfarin co-treated with vitamin K] results in increased expression of BGLAP mrna] |
| dt724 | 5280483 | Vitamin K | 847 | CAT | Rattus norvegicus (Norway rat) | 33063951 | Vitamin K inhibits the reaction [9,10-dimethyl-1,2-benzanthracene results in decreased activity of CAT protein] |
| dt725 | 5280483 | Vitamin K | 595 | CCND1 | Rattus norvegicus (Norway rat) | 23117658 | Quercetin inhibits the reaction [[warfarin co-treated with vitamin K] results in increased expression of CCND1 mrna]|[warfarin co-treated with vitamin K] results in increased expression of CCND1 mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT03358706 | A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis | PHASE1 | TERMINATED | Janssen Research & Development, LLC | Crohn Disease|Ulcerative Colitis | DRUG: Ustekinumab IV Infusion|DRUG: Ustekinumab S… | Details |
| NCT01235325 | The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients | PHASE4 | COMPLETED | University College Cork | Supplementation|Bone Health|Crohn's Disease | DIETARY_SUPPLEMENT: phylloquinone (vitamin K1)|DI… | Details |
| JPRN-UMIN000006915 | Randomized controlled trial for the management of osteoporosis in inflammatory bowel disease - The management of osteoporosis in inflammatory bowel disease | NULL | Not Recruiting | Department of Gastroenterology, Osaka University Graduate School of Medicine | Inflammatory bowel disease | Bisphosphonate (risedoronate)Vitamin K (menatetre… | Details |
| NCT05668013 | A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease | PHASE2 | ACTIVE_NOT_RECRUITING | Teva Branded Pharmaceutical Products R&D LLC | Crohn Disease|Colitis, Ulcerative | DRUG: TEV-48574 Dose Regimen A|DRUG: TEV-48574 Do… | Details |
| NCT05666960 | R-3750 in Patients With Mild to Moderate Ulcerative Colitis | PHASE1 | RECRUITING | Rise Therapeutics LLC | Ulcerative Colitis Chronic Mild|Ulcerative Coliti… | DRUG: R-3750 | Details |
| NCT05638347 | A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect. | PHASE1 | COMPLETED | Atridia Pty Ltd. | Inflammatory Bowel Disease | DRUG: HRS-7085 tablets|DRUG: Placebo tablet | Details |
| NCT07168434 | Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome | PHASE3 | RECRUITING | Biocodex | IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… | DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… | Details |
| NCT05611671 | A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC | PHASE2 | ACTIVE_NOT_RECRUITING | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | Inflammatory Bowel Diseases|Colitis, Ulcerative | DRUG: MORF-057|DRUG: Placebo | Details |
| NCT05549323 | A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis | PHASE1 | TERMINATED | Pfizer | Ulcerative Colitis | DRUG: PF-07054894|DRUG: Placebo | Details |
| NCT05536440 | A Study to Learn About Study Medicine Called PF-07261271 in Healthy People | PHASE1 | COMPLETED | Pfizer | Healthy | DRUG: PF-07261271|DRUG: Placebo | Details |
| NCT05509777 | A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease | PHASE3 | RECRUITING | Eli Lilly and Company | Crohn's Disease | DRUG: Mirikizumab | Details |
| NCT05499130 | A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease | PHASE2 | COMPLETED | Teva Branded Pharmaceutical Products R&D, Inc. | Crohn Disease|Colitis, Ulcerative | DRUG: TEV-48574|DRUG: Placebo | Details |
| NCT05466890 | Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) | PHASE2 | ACTIVE_NOT_RECRUITING | Palatin Technologies, Inc | Ulcerative Colitis|Ulcerative Colitis Acute|Ulcer… | DRUG: PL8177 Placebo|DRUG: PL8177 | Details |
| NCT05452304 | AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease | PHASE1 | COMPLETED | AstraZeneca | Healthy Subjects|Crohns Disease | BIOLOGICAL: AZD7798|BIOLOGICAL: Placebo | Details |
| NCT05389709 | A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting | NULL | COMPLETED | Bayer | Functional Gastrointestinal Disorders Such as Irr… | DRUG: Iberogast (STW5-II, BAY98-7410) | Details |
| NCT05316220 | A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis | PHASE3 | WITHDRAWN | AbbVie | Ulcerative Colitis (UC) | DRUG: Mesalamine|DRUG: Placebo | Details |
| NCT05291689 | A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC | PHASE2 | COMPLETED | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | Inflammatory Bowel Diseases|Colitis, Ulcerative | DRUG: MORF-057 | Details |
| NCT05242484 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | PHASE2 | ACTIVE_NOT_RECRUITING | Janssen Research & Development, LLC | Colitis, Ulcerative | BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… | Details |
| NCT05242471 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease | PHASE2 | ACTIVE_NOT_RECRUITING | Janssen Research & Development, LLC | Crohn's Disease | BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… | Details |
| NCT05239702 | Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases | EARLY_PHASE1 | UNKNOWN | Zhejiang University | Crohn Disease|Ulcerative Colitis|Dermatomyositis|… | BIOLOGICAL: CD7 CAR T-cells | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Maternal and Neonatal Hemorrhage From Vitamin K Deficiency in the Setting of Cr…
PMID: 40048733
Year: 2025
Relationship Type:
Association
Score: 6.5
BACKGROUND: Patients with inflammatory bowel disease, particularly Crohn disease (CD), are at increased risk of fat malabsorption and fat-soluble vit…
Pregnane X Receptor Signaling Pathway and Vitamin K: Molecular Mechanisms and C…
PMID: 38667296
Year: 2024
Relationship Type:
Treatment
Score: 6.5
This review explores the likely clinical impact of Pregnane X Receptor (PXR) activation by vitamin K on human health. PXR, initially recognized as a …
Low Vitamin K and Vitamin D Dietary Intake in Patients with Inflammatory Bowel …
PMID: 37049518
Year: 2023
Relationship Type:
Association
Score: 6.5
The inadequate dietary intake of Vitamin D and Vitamin K is an easily reversible factor favoring IBD-associated bone loss, but data on Vitamin K are …
Ameliorating Effects of Vitamin K2 on Dextran Sulfate Sodium-Induced Ulcerative…
PMID: 36769323
Year: 2023
Relationship Type:
Mechanism
Score: 6.5
Ulcerative colitis (UC) is a chronic recurrent inflammatory illness of the gastrointestinal system. The purpose of this study was to explore the alle…
Role of Vitamin K in Intestinal Health
PMID: 35069573
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Intestinal diseases, such as inflammatory bowel diseases (IBDs) and colorectal cancer (CRC) generally characterized by clinical symptoms, including m…
The Impact of Vitamin K2 (Menaquionones) in Children's Health and Diseases: A R…
PMID: 35053702
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Vitamin K2 activates vitamin K-dependent proteins that support many biological functions, such as bone mineralization, the inhibition of vascular sti…
[Vitamin K2 influences several diseases]
PMID: 26321585
Year: 2015
Relationship Type:
Clinical Trial
Score: 6.3
In this paper we discuss the evidence of vitamin K2 deficiency which is a factor in several chronic diseases like diabetes, osteoporosis, cancer, inf…
Vitamin K deficiency bleeding leading to the diagnosis of Crohn's disease
PMID: 25117110
Year: 2014
Relationship Type:
Association
Score: 6.3
We report the case of a 45 year old man who came to Emergency Room of Polyclinic for sudden onset of localized ecchymosis and widespread hematomas. H…
Early vitamin K deficiency bleeding in a neonate associated with maternal Crohn…
PMID: 25073494
Year: 2014
Relationship Type:
Association
Score: 6.3
We report herein a case of early vitamin K deficiency bleeding (VKDB) in a neonate associated with maternal Crohn's disease. A female neonate was bor…